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Abstract Data from two phase 3 studies of eribulin were
pooled in analyses initially requested by the European
Medicines Agency to assess whether specific patient sub-
groups, previously treated with an anthracycline and a
taxane, benefited from eribulin. Study 305/EMBRACE
included women after two-to-five lines of chemotherapy
for advanced breast cancer who were randomized to erib-
ulin mesylate (1.4 mg/m2 on days 1 and 8 every 21 days)
or treatment of physician’s choice. In Study 301, patients
who had received up to two prior chemotherapy regimens
for advanced disease were randomized to eribulin (as
above) or capecitabine (1.25 g/m2 b.i.d. on days 1–14
every 21 days). In the pooled population, overall survival
(OS), progression-free survival and response rates were
analysed in the intent-to-treat population and selected
subgroups. Overall, 1,062 patients were randomized to
eribulin and 802 patients to control. Median OS was
15.2 months with eribulin versus 12.8 months with control
(hazard ratio [HR] 0.85; 95 % CI 0.77, 0.95; P = 0.003).
In all subgroups assessed, OS data favoured eribulin; sig-
nificant improvements occurred in some subgroups, nota-
bly in women with human epidermal growth factor
receptor 2 (HER2)-negative disease (HR 0.82; P = 0.002),
although the effect in those with HER2-negative but hor-
mone-receptor-positive disease did not reach statistical
significance; benefits were also seen, among others, in
those with estrogen-receptor-negative and triple-negative
disease. Eribulin improves OS in various patient subgroups
with advanced/metastatic breast cancer who had previously
received an anthracycline and a taxane. Women with
HER2-negative disease are among those who may obtain
benefit from eribulin.
Keywords Eribulin mesylate  Halaven  Metastatic
breast cancer  Pooled analysis
Introduction
Despite improvements in treatment, long-term survival for
women with advanced breast cancer remains poor, with a
5-year survival rate of less than 25 % for those presenting
with metastatic disease [1]. Effective treatment options
with proven survival benefits are therefore required for
these patients. It is, however, often difficult for clinicians to
make evidence-based judgements regarding the most
effective treatment for such patients. For example, it is
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increasingly common for patients to receive anthracycline-
and/or taxane-based regimens in the adjuvant or first-line
metastatic settings. A systematic review by Oostendorp
et al. in 2011 demonstrated the paucity of good-quality,
randomized clinical trial data on chemotherapy for patients
with advanced disease who have previously received an
anthracycline and a taxane [2]. Available evidence suggests
that sequential single agent treatment is generally prefer-
able to combination treatment [3, 4]. In addition, there is
some evidence that re-challenging patients with an
anthracycline or a taxane may be beneficial in the meta-
static setting [5, 6], particularly when the disease-free
interval has been long; the evidence base is, however,
limited. This lack of high-quality, evidence-based data has
precluded guidelines from giving clear recommendations
as to the sequence in which potentially active chemother-
apy agents are best used in women with metastatic
breast cancer who have received an anthracycline and a
taxane [7, 8].
Since publication of the aforementioned systematic
review [2], two phase 3, randomized, controlled trials of
eribulin in women with advanced/metastatic breast cancer
who have previously received an anthracycline and a tax-
ane have been reported. In Study 305/EMBRACE, eribulin
was associated with improved overall survival (OS) com-
pared with treatment of physician’s choice (TPC) in
patients who had received at least two prior chemotherapy
regimens for advanced disease, and no more than five
cytotoxic regimens that had included an anthracycline and
a taxane [9]. These results were confirmed in an updated
analysis (based on a 77 % event rate) that was requested by
US and European regulatory authorities [9]. In Study 301,
which involved patients in an earlier line setting than Study
305/EMBRACE, a statistically significant survival benefit
for eribulin over capecitabine was not shown (manuscript
in press, J Clin Oncol). In a pre-specified subgroup ana-
lysis, however, median OS was longer with eribulin than
with capecitabine in patients with human epidermal growth
factor receptor 2 (HER2)-negative or triple-negative breast
cancer. By contrast, subgroup analyses in Study
305/EMBRACE did not show a significant difference in
these populations in either the initial (55 % event rate) or
updated analysis (Online Resource 1). A similar hazard
ratio (HR) in favour of eribulin was observed in patients
with triple-negative breast cancer in the initial analysis of
Study 305/EMBRACE and Study 301 (HR 0.71 and 0.70,
respectively) [10], but not in the updated analysis of Study
305/EMBRACE. In patients with HER2-positive disease,
there was a trend towards a benefit with eribulin in the
initial analysis of Study 305/EMBRACE, which became
significant in the updated analysis (Online Resource 1);
there was no evidence of a benefit in Study 301 (HR 0.97)
[10]. The reasons for the differences between the two
studies are unclear, but treatment decisions would be aided
by greater clarity regarding the effect of eribulin in specific
subgroups of women with advanced/metastatic breast
cancer.
To provide more information on the efficacy of eribulin
in patients with breast cancer with respect to HER2 status,
the European Medicines Agency (EMA) requested a
pooled analysis of Study 305/EMBRACE and Study 301
by HER2 and triple-negative disease status. Here, we
report the results of this and additional subgroup analyses
that provide further insights regarding the effect of eribulin
in patients with advanced breast cancer.
Methods
Study 305/EMBRACE
Detailed methods for Study 305/EMBRACE have been
published previously [9, 10]. In brief, this was an open-
label, randomized study of eribulin mesylate (1.4 mg/m2
i.v. [equivalent to 1.23 mg/m2 eribulin expressed as free
base] on days 1 and 8 every 21 days) versus TPC in women
with locally recurrent or metastatic breast cancer. Patients
were randomized in a 2:1 ratio to eribulin and TPC,
respectively. A key inclusion criterion was that patients had
received between two and five previous chemotherapy
regimens (including an anthracycline and a taxane), two or
more of which were for locally recurrent or metastatic
disease. Known brain metastases, unless treated and stable,
and pre-existing neuropathy of grade three or higher were
among the key exclusion criteria. Study treatment contin-
ued until: disease progression; unacceptable toxic effects;
the patient or physician requested discontinuation; or
serious non-compliance with the protocol. The primary
objective was to compare OS between the two treatment
arms.
Study 301
Detailed methods for Study 301 have been presented [11;
manuscript in press, J Clin Oncol]. This was an open-label,
randomized study of eribulin mesylate (1.4 mg/m2 i.v. on
days 1 and 8 every 21 days) versus capecitabine (1.25 g/m2
b.i.d. on days 1–14 every 21 days; 1:1 ratio) as first-, second-,
or third-line chemotherapy for advanced breast cancer.
Inclusion criteria included: no more than three prior che-
motherapy regimens, of which no more than two were for
advanced or metastatic disease; and prior therapy with an
anthracycline and a taxane. Among the exclusion criteria
were prior capecitabine treatment and radiation therapy
encompassing more than 30 % of marrow. Similar to Study
305/EMBRACE, patients received study treatment until
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disease progression, unacceptable toxicity, or the patient or
physician requested discontinuation of treatment. In contrast
to Study 305/EMBRACE, Study 301 had co-primary end-
points of OS and progression-free survival (PFS). The study
would be defined positive if, at final analysis, either OS with
eribulin was statistically significantly better (P B 0.0372)
than with capecitabine, or PFS with eribulin was statistically
significantly better (P B 0.01) than with capecitabine, and
HR for OS (eribulin/capecitabine) was less than 1.0.
Ethics
Both Study 305/EMBRACE and Study 301 required
informed patient consent and approval by ethical review
boards, and were conducted in line with the World Medical
Association revised Declaration of Helsinki and guidelines
of the International Conference on Harmonisation of Good
Clinical Practice.
Pooled analysis
The objective of this pooled analysis (prompted initially by
a request from the EMA for an analysis by HER2 status)
was to assess OS in the intent-to-treat (ITT) population and
in important subgroups of patients with breast cancer. Data
from the updated analysis (based on 77 % event rate) of
Study 305/EMBRACE were used in this analysis. The
analysis included subgroups based on: HER2 status (posi-
tive, negative or unknown); estrogen-receptor (ER) status
(positive, negative or unknown); progesterone-receptor
status (positive, negative, unknown or data not shown); the
number of organs involved (two or fewer, or more than
two); presence of visceral disease (yes or no); and taxane
resistance (refractory: yes or no). Patients were defined as
refractory to taxanes if they experienced progression within
60 days after taking their last taxane dose. Other subgroups
were patients with or without triple-negative disease (or
unknown) and those who were HER2-negative but hor-
mone-receptor-positive. Response rates and PFS were also
assessed for the overall population and the various sub-
groups. Investigator review data were used for these anal-
yses because the independent review committee data may
have been underestimated owing to informative censoring
(and were available only after 55 % of events had been
reached in Study 305).
In this analysis, adjustment for study was necessary due
to the 2:1 randomization in Study 305/EMBRACE. This
was to overcome bias that would otherwise be introduced
owing to the larger number of eribulin patients receiving
treatment in a later treatment-line setting. Thus, median OS
and PFS data were derived from survival curves adjusted
by study using methodology outlined previously by Chang
et al. and Makuch [12, 13]. Cox regression analysis was
used to calculate HRs for OS and PFS stratified as per the
original studies with the addition of stratification by study.
Thus, data were stratified by region (region 1: North
America, Western Europe, Australia; region 2: Latin and
South America; region 3: Eastern Europe; region 4: Asia),
prior capecitabine use and study. Analyses in the overall
population were additionally stratified for HER2 status. For
analysis of patients with HER2-negative disease, data were
stratified for triple-negative disease, in addition to region,
prior capecitabine and study. P values for HRs were based
on two-sided stratified log-rank tests and may be consid-
ered nominal owing to the unplanned nature of the ana-
lysis. Interaction analyses were performed for subgroup
data using Cox models. Differences in investigator-
reviewed response rates were tested by the Cochrane–
Mantel–Haenszel test stratified by study.
Results
Patients
In total, 1,062 patients were randomized to eribulin and
802 patients to control (TPC or capecitabine). Patients in
the eribulin and control groups were generally well mat-
ched (Table 1). In the eribulin group, patients had most
commonly received two prior chemotherapy regimens for
advanced disease (35.1 % compared with 29.4 % in the
control group), whereas patients had most commonly
received one regimen for advanced disease in the control
group (37.4 % compared with 27.1 % in the eribulin
group). This reflects that patients with different levels of
pre-treatment were eligible for the individual studies.
Accordingly, more than half of the patients in Study 301
had received only one prior regimen for advanced disease,
whereas in Study 305/EMBRACE patients had most
commonly received two regimens for advanced disease.
Efficacy
The survival curve for OS in the total population showed
an early separation in favour of eribulin that was main-
tained throughout the analysis period (Fig. 1). Median OS
in the ITT population was 15.2 months in the eribulin arm
compared with 12.8 months in the control arm, a difference
of 2.4 months; analysis showed a significant benefit in
favour of eribulin (HR 0.85; P = 0.003). In addition,
treatment with eribulin was associated with apparent ben-
efits in OS across all patient subgroups (Fig. 2). A 2.9-
month difference in OS was found in patients with HER2-
negative disease (median OS, eribulin vs control: 15.2 vs
12.3 months, respectively; HR 0.82; P = 0.002), although
this effect did not reach statistical significance in patients
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with HER2-negative but hormone-receptor-positive disease
(P = 0.060). The difference in OS for those with HER2-
positive disease favoured eribulin but did not reach statis-
tical significance (13.5 vs 12.2 months; HR 0.82;
P = 0.135); the patient numbers were, however, smaller in
this subgroup than in the HER2-negative group (HER2-
positive, eribulin n = 169, control n = 123; HER2-nega-
tive, eribulin n = 748, control n = 572). In patients with
triple-negative disease, median survival was 4.7 months
longer in patients treated with eribulin than in those who
received control (median OS: 12.9 vs 8.2 months; HR 0.74;
P = 0.006). In addition, median OS was longer with
eribulin than with control, regardless of ER status (ER-
positive: median OS 16.1 vs 14.3 months, HR 0.86,
P = 0.038; ER-negative: median OS 12.9 vs 10.1 months,
HR 0.79, P = 0.007).
Considering other subgroups, not based on receptor
status, a benefit in favour of eribulin over control treatment
was found in patients with more than two organs involved
(median OS 13.1 vs 10.5 months; HR 0.77; P \ 0.001).
Patient subgroups based on the presence or absence of
visceral disease also had, on average, longer survival times
if patients were treated with eribulin than if they received
control (visceral disease: median OS 14.3 vs 12.2 months,
HR 0.89, P = 0.037; non-visceral disease: median OS 18.8
vs 16.6 months, HR 0.72, P = 0.045). A 3.0 month dif-
ference in survival in favour of eribulin occurred in patients
not refractory to taxane treatment (median OS 17.4 vs
14.4 months; HR 0.81; P = 0.007); the difference in OS
did not reach significance in patients who were refractory
to taxanes (median OS 12.8 vs 11.3 months; HR 0.91;
P = 0.206).
Interaction analysis showed clearest evidence of a
greater benefit for eribulin in the case of patients with a
higher burden of disease, as indicated by more than two
organs involved (P = 0.023 vs those with two or fewer
organs involved). Interaction P values were relatively low
(compared with interaction data in most of the other tested
subgroups, see Fig. 2) in patients with triple-negative dis-
ease (P = 0.154 vs patients without triple-negative breast
cancer) and those with ER-negative disease (P = 0.159 vs
other patients).
As in the individual analyses of Study 305/EMBRACE
and Study 301, eribulin appeared to have a greater impact
on OS than did PFS. Benefits for eribulin in terms of PFS
were, however, apparent in the overall population, patients
with HER2-negative and triple-negative disease, those who
were ER-positive and those with more than two organs
involved (Table 2). The magnitudes of these differences
were small and interaction analysis did not indicate that the
benefits were specific to these subgroups.






Median age, years (range) 55.0 (24–85) 54.0 (26–81)
Race, n (%)
Black 35 (3.3) 30 (3.7)
White 966 (91.0) 728 (90.8)
Asian/Pacific Islander 21 (2.0) 20 (2.5)
Other 40 (3.8) 24 (3.0)
ECOG performance status, n (%)
0 467 (44.0) 333 (41.5)
1 537 (50.6) 427 (53.2)
2 50 (4.7) 38 (4.7)
3 0 1 (0.1)
Number of prior chemotherapy regimens
0 1 (0.1) 0
1 148 (13.9) 153 (19.1)
2 384 (36.2) 345 (43.0)
3 260 (24.5) 161 (20.1)
C4 267 (25.1) 142 (17.7)
Number of prior chemotherapy regimens for advanced disease
0 117 (11.0) 104 (13.0)
1 288 (27.1) 300 (37.4)
2 373 (35.1) 236 (29.4)
[2 284 (26.7) 161 (20.1)
Number of organs involved, n (%)
1 198 (18.6) 127 (15.8)
2 346 (32.6) 259 (32.3)
3 298 (28.1) 226 (28.2)
C4 218 (20.5) 189 (23.6)
Site of disease, n (%)
Visceral 880 (82.9) 694 (86.5)
Non-visceral only 171 (16.1) 101 (12.6)
Missing 11 (1.0) 7 (0.9)
HER2 status, n (%)
Positive 169 (15.9) 123 (15.3)
Negative 748 (70.4) 572 (71.3)
Unknown 145 (13.7) 107 (13.3)
ER status, n (%)
Positive 595 (56.0) 449 (56.0)
Negative 376 (35.4) 288 (35.9)
Unknown 91 (8.6) 65 (8.1)
Triple-negative disease, n (%) 243 (22.9) 185 (23.1)
Taxane refractory, n (%)a
Yes 530 (49.9) 401 (50.0)
No 532 (50.1) 401 (50.0)
ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, HER2
human epidermal growth factor receptor 2, ITT intent-to-treat, PR pro-
gesterone receptor
a Refractory defined as progressed within 60 days after taking the last
dose
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There were few differences between the treatment
groups in objective response rates (ORRs) or clinical
benefit rates (CBRs) in the ITT population and in the
various subgroups (Online Resource 2). In the ITT popu-
lation, the ORRs were 14.9 % and 16.4 %, and the CBRs
were 30.9 % and 30.3 %, in the eribulin and control
groups, respectively; these differences were not statistically
significant. The only significant differences were for CBRs
in favour of eribulin in patients with ER-positive disease
(33.4 % vs 29.3 %, P = 0.046) and those with HER2-
negative but hormone-receptor-positive disease (33.6 % vs
28.3 %, P = 0.036).
Safety
Tolerability and safety data for Study 305/EMBRACE and
Study 301 have been detailed elsewhere [9, 10]. When the
data were pooled, no notable differences in adverse events
from those reported in the primary publications were
revealed. In the pooled analysis, serious adverse events
occurred in similar proportions in the two groups (eribulin
21.1 %; control 22.6 %). In total, 10.5 % of patients in the
eribulin group had an adverse event that led to discontin-
uation, compared with 12 % in the control group.
Discussion
This pooled analysis showed that eribulin was associated
with improved OS in the total population compared with
control; it also suggested that certain patients with
advanced/metastatic breast cancer may gain a particular
benefit from eribulin.
Significant differences in median OS in favour of erib-
ulin over control treatment were seen in most of the sub-
groups assessed. Women with HER2-negative disease
gained a significant survival benefit from eribulin, and a
benefit was also found regardless of triple-negative status
(a lower HR was found in patients with triple-negative
disease). This was also true of patients with ER-positive or
ER-negative disease, although the HR indicating a benefit
for eribulin was more favourable in the ER-negative sub-
group than in the ER-positive subgroup. Generally, similar
results were found in an analysis of patients who had
previously received one or more lines of chemotherapy for
advanced disease (Online Resource 3). A numerical dif-
ference in OS in favour of eribulin was seen in patients
with HER2-positive breast cancer, and the HR was very
similar to that observed in women with HER2-negative
disease. The difference between treatments in the HER2-
positive group was not statistically significant; patient
numbers were, however, substantially smaller in this sub-
group, resulting in a wide confidence interval.
Considering other patient subgroups, those with more
than two affected organs gained a clear additional survival
benefit from eribulin treatment compared with control. In
one report, the response to chemotherapy tends to decrease
as the number of organs involved increases [14]. Improved
response rates in patients with multiple organs involved


































































































Median OS, eribulin vs control: 15.2 vs 12.8 months 
HR 0.85; 95 % CI 0.77, 0.95; P = 0.003
Fig. 1 OS curve in the total intent-to-treat population stratified by study. Survival curve adjusted by study
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docetaxel in patients with advanced breast cancer reported
the highest response rate in those with more than two
organs involved (83.3 %, compared with 62.5 % in those
with one organ involved and 45.5 % in those with two
organs involved) [15]. The reasons for the results observed
in the present study are unclear. Patients with multiple
organs involved are more likely to have triple-negative
disease [16–18]. It could be, therefore, that the apparent
survival benefits with eribulin observed among patients
with more than two organs involved were influenced by a
high proportion of patients with triple-negative breast
cancer in that subgroup; this observation may, alterna-
tively, be due to chance alone. This finding is, moreover, of
limited clinical relevance, because the number of organs
involved does not typically impact on treatment selection.
Patients also benefited from eribulin regardless of
whether they had visceral or non-visceral disease. In
addition, those who were not refractory to taxanes had
improved OS if treated with eribulin compared with
control. As expected, the current analysis did not reveal
any notable differences in safety compared with the pre-
viously reported data.
Interaction analyses, which were not part of the initial
pooled analysis plan, showed a distinct additional benefit of
eribulin over control treatment for patients with more than
two organs involved compared with other patients. In
addition, relatively low interaction P values in the ER-
negative and triple-negative subgroups suggested there
may be an enhanced benefit from eribulin in these groups.
Statistically significant differences in PFS in favour of
eribulin over control were found in the ITT population and
in some of the subgroups in which significant differences in
OS were found. The magnitudes of the differences were,
however, small and not clinically significant. Why eribulin
may be associated with more meaningful differences in OS
than in PFS is not clearly understood.
Given the lack of high-quality studies in patients with
advanced breast cancer previously treated with taxanes and




HR: 0.85; 95% CI: 0.77, 0.95; 
  P = 0.003 
(interaction)
HR: 0.82; 95% CI: 0.62, 1.06; 
  P = 0.135
HR: 0.82; 95% CI: 0.72, 0.93; 
  P = 0.002 (P = 0.432)
HR: 0.86; 95% CI: 0.74, 1.01; 
  P = 0.060
HR: 0.86; 95% CI: 0.74, 0.99; 
  P = 0.038 (P = 0.659)
HR: 0.79; 95% CI: 0.66, 0.94; 
  P = 0.007 (P = 0.159)
HR: 0.74; 95% CI: 0.60, 0.92; 
  P = 0.006 (P = 0.154)
HR: 0.86; 95% CI: 0.76, 0.98; 
  P = 0.024 (P = 0.599)
HR: 0.93; 95% CI: 0.80, 1.09; 
  P = 0.390
HR: 0.77; 95% CI: 0.66, 0.89; 
  P < 0.001 (P = 0.023)
HR: 0.89; 95% CI: 0.79, 0.99; 
  P = 0.037 (P = 0.313)
HR: 0.72; 95% CI: 0.52, 0.99; 
  P = 0.045
HR: 0.91; 95% CI: 0.78, 1.06; 
P = 0.206
Overall population 
  (eribulin, n = 1,602; control, n = 802)
HER2-positive 
  (eribulin, n = 169; control, n = 123)
HER2-negative 
  (eribulin, n = 748; control, n = 572)
HER2-negative and hormone-receptor-positive 
  (eribulin, n = 496; control, n = 379)
ER-positive 
  (eribulin, n = 595; control, n = 449)
ER-negative 
  (eribulin, n = 376; control, n = 288)
Triple-negative 
  (eribulin, n = 243; control, n = 185)
Non-triple-negative 
  (eribulin, n = 707; control, n = 543)
  (eribulin, n = 544; control, n = 386)
> 2 organs involved 
  (eribulin, n = 516; control, n = 415)
Visceral disease 
  (eribulin, n = 880; control, n = 694)
Non-visceral disease 
  (eribulin, n = 171; control, n = 101)
Taxane-refractory 
  (eribulin, n = 530; control, n = 401)
Non-taxane-refractory 
  (eribulin, n = 532; control, n = 401)
HR: 0.81; 95% CI: 0.69, 0.94; 
  P = 0.007 (P = 0.309)
Fig. 2 HRs for OS in the overall population and subgroups based on
HER2 status, presence of triple-negative disease, number of organs
involved, presence of visceral disease and resistance to taxane
treatment. HR based on Cox proportional hazards stratified by
geographic region, prior capecitabine use and study (overall
population additionally stratified by HER2 status; HER2-negative
population additionally stratified by triple-negative status). P value
based on stratified log-rank test. Interaction P values (Cox model) are
given for subgroups for which significant differences were apparent
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anthracyclines, the data presented here add to the evidence
base for clinicians. The main strength of the current ana-
lysis is that the data are derived from well-designed, ran-
domized studies providing high-quality evidence. Pooling
the data from these controlled studies has provided further
insights into subgroups that may gain a particular advan-
tage from eribulin treatment. Specifically, the individual
studies were not powered to demonstrate differences in
patient subgroups. This is especially relevant in the context
of HER2 status. Both Study 305/EMBRACE and Study
301 included patients with either HER2-positive or HER2-
negative disease. This reflected trial design and clinical
practice at a time when HER2-targeted therapy was not
routinely continued in combination with successive che-
motherapy regimens and there were not multiple agents
targeting the HER family. The pooled analysis gave us
sufficient numbers of patients to look at outcomes by HER-
and ER-receptor status.
There are, however, limitations to the current analysis.
First, this was an unplanned analysis, albeit one undertaken
initially at the request of a regulatory body. Pooling the
data was complicated by the fact the two studies involved
different patient groups, in particular with regard to the
extent of prior chemotherapy. The analytical plan did,
however, take into account this difference to some extent.
Treatment in the control arms was also not the same, with
Study 305/EMBRACE using TPC and Study 301 using
capecitabine. Nevertheless, the subgroup data presented
here provide useful insights into specific subgroups of
patients with advanced breast cancer who may gain a
greater benefit in terms of survival than others from erib-
ulin treatment.
Patients with HER2-negative disease represent about
85 % of women with metastatic breast cancer [19], and so
confirmation from the pooled analysis that these women
benefit significantly from eribulin is of particular clinical
relevance. The fact that women with triple-negative breast
cancer may derive a particularly strong benefit from erib-
ulin is worthy of further investigation. Interestingly,
in vitro and in vivo data suggest that eribulin treatment
may promote transition of triple-negative breast cancer
cells from a mesenchymal to an epithelial phenotype, and
that this is coupled with a decrease in the ability of these
cells to migrate and therefore metastasize [20]. The added
OS benefit of eribulin in women with HER2-positive dis-
ease remains unclear because it did not reach statistical
significance. As noted previously, patients with HER2-
positive disease in Study 305/EMBRACE experienced a
significant benefit with eribulin in the updated analysis,
whereas there was no such benefit in Study 301. There is no
clear explanation for this difference between the studies;
the impact of post-progression therapies is being investi-
gated. The question of the single agent activity of eribulin
in women with HER2-positive metastatic breast cancer is,
Table 2 PFS in the ITT
population and selected
subgroups
ER estrogen receptor, CI
confidence interval, HER2
human epidermal growth factor
receptor 2, HR hazard ratio, ITT
intent-to-treat, PFS progression-
free survival, PR progesterone
receptor
a Based on curve adjusted by
study
b Cox proportional hazards
stratified by geographic region,
prior capecitabine use and study
(overall population additionally
stratified by HER2 status;
HER2-negative population
additionally stratified by triple-
negative status)
c Based on stratified log-rank
test
d Interaction P values (Cox
model) are given for subgroups
for which significant differences
were apparent
Median PFS, monthsa HR (95 % CI)b P valuec P value
(interaction)d
Eribulin Control
Overall population 4.0 3.4 0.90 (0.81, 0.997) 0.046
HER2 status
Positive 4.0 4.7 1.02 (0.78, 1.34) 0.865 0.185
Negative 3.7 3.0 0.84 (0.74, 0.95) 0.006
HER2 negative/
hormone receptor positive
4.2 3.4 0.87 (0.75, 1.02) 0.084
ER status
Positive 4.2 3.7 0.86 (0.74, 0.99) 0.040 0.527
Negative 3.0 2.9 0.89 (0.75, 1.06) 0.212
Triple negative 2.8 2.6 0.78 (0.63, 0.96) 0.018 0.117
Non-triple negative 4.2 3.8 0.926 (0.82, 1.04) 0.21
Number of organs involved
B2 4.2 4.2 0.92 (0.79, 1.07) 0.290 0.468
[2 3.7 2.8 0.86 (0.74, 0.99) 0.043
Visceral disease
Yes 3.8 3.3 0.94 (0.84, 1.05) 0.274
No 4.7 4.3 0.75 (0.56, 1.02) 0.065
Taxane refractory
Yes 3.5 2.8 0.90 (0.77, 1.05) 0.176
No 4.3 4.0 0.87 (0.75, 1.01) 0.079
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however, of less relevance clinically now that combination
with HER2-targeted therapy is acknowledged to be optimal
across multiple lines of therapy. Nevertheless, our data
suggest that eribulin is active as a single agent in women
with HER2-positive disease, and preliminary results in
combination with trastuzumab are encouraging [21].
Conclusion
This pooled analysis of women with advanced/metastatic
breast cancer confirms the significant survival benefit of
eribulin compared with control following treatment with a
taxane and an anthracycline in either the adjuvant or the
metastatic setting. This survival benefit holds true across
most patient subgroups. Indeed, women with HER2-nega-
tive or triple-negative disease gained a particular benefit;
the effects in patients with HER2-negative but hormone-
receptor-positive disease were somewhat less robust.
Similar findings occurred in the subgroup of patients
receiving eribulin in a second-line or later setting.
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